WallStSmart

The Boeing Company (BA)vsBristol-Myers Squibb Company (BMY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Boeing Company generates 86% more annual revenue ($89.46B vs $48.19B). BMY leads profitability with a 14.6% profit margin vs 2.5%. BMY appears more attractively valued with a PEG of 2.26. BMY earns a higher WallStSmart Score of 64/100 (C+).

BA

Buy

51

out of 100

Grade: C-

Growth: 6.7Profit: 3.0Value: 2.0Quality: 4.0
Piotroski: 5/9Altman Z: 1.01

BMY

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.5Value: 10.0Quality: 4.5
Piotroski: 6/9Altman Z: 1.42
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BASignificantly Overvalued (-1083.9%)

Margin of Safety

-1083.9%

Fair Value

$16.86

Current Price

$199.61

$182.75 premium

UndervaluedFair: $16.86Overvalued
BMYUndervalued (+63.0%)

Margin of Safety

+63.0%

Fair Value

$161.93

Current Price

$58.94

$102.99 discount

UndervaluedFair: $161.93Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BA2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
57.1%10/10

Revenue surging 57.1% year-over-year

Market CapQuality
$154.36B9/10

Large-cap with strong market position

BMY5 strengths · Avg: 8.6/10
Return on EquityProfitability
40.4%10/10

Every $100 of equity generates 40 in profit

Market CapQuality
$120.03B9/10

Large-cap with strong market position

P/E RatioValuation
17.0x8/10

Attractively priced relative to earnings

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

Free Cash FlowQuality
$1.60B8/10

Generating 1.6B in free cash flow

Areas to Watch

BA4 concerns · Avg: 2.5/10
Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

Profit MarginProfitability
2.5%3/10

2.5% margin — thin

PEG RatioValuation
6.532/10

Expensive relative to growth rate

P/E RatioValuation
79.2x2/10

Premium valuation, high expectations priced in

BMY4 concerns · Avg: 2.8/10
PEG RatioValuation
2.264/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.3%4/10

1.3% revenue growth

Altman Z-ScoreHealth
1.422/10

Distress zone — elevated risk

Debt/EquityHealth
2.551/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : BA

The strongest argument for BA centers on Revenue Growth, Market Cap. Revenue growth of 57.1% demonstrates continued momentum.

Bull Case : BMY

The strongest argument for BMY centers on Return on Equity, Market Cap, P/E Ratio.

Bear Case : BA

The primary concerns for BA are Return on Equity, Profit Margin, PEG Ratio. A P/E of 79.2x leaves little room for execution misses. Debt-to-equity of 9.92 is elevated, increasing financial risk.

Bear Case : BMY

The primary concerns for BMY are PEG Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.

Key Dynamics to Monitor

BA profiles as a hypergrowth stock while BMY is a value play — different risk/reward profiles.

BA carries more volatility with a beta of 1.10 — expect wider price swings.

BA is growing revenue faster at 57.1% — sustainability is the question.

BMY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

BMY scores higher overall (64/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Boeing Company

INDUSTRIALS · AEROSPACE & DEFENSE · USA

The Boeing Company is an American multinational corporation that designs, manufactures, and sells airplanes, rotorcraft, rockets, satellites, telecommunications equipment, and missiles worldwide. The company also provides leasing and product support services.

Bristol-Myers Squibb Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Visit Website →

Want to dig deeper into these stocks?